[Therapy with antipsychotic drugs as a risk factor for XXXX in @entity161 : a case-control study].

@entity1 @entity1088 @entity6 @entity1674 @entity1017 @entity161 @entity1037 @entity413 @entity1090
BACKGROUND AND OBJECTIVES: Atypical antipsychotics have been related with hyperglycaemia, @entity6 , @entity1017 and lipid alterations in some @entity1 . This study analyzed whether continuous treatment with @entity1090 , @entity1037 , or @entity1088 entails a risk of @entity413 or lipid metabolism alterations in @entity161 @entity1 . @entity1 AND METHOD: @entity1 included in this study were @entity161 who had received mono-therapeutic with @entity1088 , @entity1037 or @entity1090 for a period of 1 to 3 years. Those @entity161 @entity1 who were diagnosed as @entity6 during psychiatric treatment and those who showed fasting glycemia greater than or equal to 126 mg/dl in two consecutive measurements were considered cases. The remaining @entity161 @entity1 who were receiving treatment and did not show these alterations were considered controls. RESULTS: In the adjusted analysis (multivariate logistic regression) of the effect of antipsychotic treatment on the presence of @entity6 , which also assessed age and body-mass index, the adjusted odds ratio (OR) for @entity1037 relative to @entity1090 was 2.22 (95% confidence interval [CI], 1.12-4.22), (p = 0.0228); and that for @entity1088 relative to @entity1090 was 2.87 (95% CI, 1.19, 6.93), (p = 0.0192). Both results reveal a significantly greater risk for the appearance of @entity6 in @entity1 treated with @entity1037 or @entity1088 than in those treated with @entity1090 . There were significant differences in the risk of increase in @entity1674 in @entity1 receiving @entity1037 (OR = 1.34; p = 0.0075) and @entity1088 (OR = 1.58; p = 0.0028). CONCLUSIONS: The risk of the appearance of @entity6 in @entity1 treated with @entity1037 is twice as high as that in @entity1 treated with @entity1090 , and the risk in @entity1 treated with @entity1088 is nearly triple as high as that found in @entity1 treated with @entity1090 . @entity1090 appears to be a safer antipsychotic drug in the long term, with regard to the risk of alterations in @entity413 and lipid metabolism.
